SEC Form 4 · accession 0000899243-19-000740
Surface Oncology, Inc. · SURF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jessica Fees
Officer — See Remarks
Period of report
Jan 4, 2019
Accepted (ET)
Jan 8, 2019 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001718108
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 4, 2019 | M | 1,818 | $0.352 | A | 47,722 | D | |
| Common Stock | Jan 4, 2019 | M | 455 | $4.136 | A | 48,177 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.352 | Jan 4, 2019 | M | 1,818 | D | — | Sep 14, 2025 | Common Stock | 1,818 | 2,728 | D |
| Stock Option (Right to Buy)F2 | $4.136 | Jan 4, 2019 | M | 455 | D | — | Dec 9, 2026 | Common Stock | 455 | 5,455 | D |
Explanation of responses
- F125% of this option became exercisable on April 1, 2016 and the remaining 75% shall vest in 36 equal monthly installments thereafter.
- F2This option shall vest in 48 equal monthly installments after January 1, 2017.
Remarks
Principal Accounting Officer, Principal Financial Officer